Deutsche Bank set a €25.00 ($29.07) target price on Evotec (ETR:EVT) in a research note released on Thursday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
Separately, Berenberg Bank set a €28.00 ($32.56) price target on Evotec and gave the company a buy rating in a research report on Tuesday, November 12th.
EVT stock traded up €0.15 ($0.17) during trading on Thursday, hitting €18.71 ($21.75). The company had a trading volume of 2,465,690 shares, compared to its average volume of 1,360,000. The firm has a market cap of $2.80 billion and a PE ratio of 36.82. Evotec has a 1-year low of €16.23 ($18.87) and a 1-year high of €27.29 ($31.73). The firm has a 50-day moving average price of €19.84 and a 200-day moving average price of €22.13. The company has a quick ratio of 3.01, a current ratio of 3.24 and a debt-to-equity ratio of 99.79.
Evotec Company Profile
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
Read More: Dividend
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.